, , , , , ,

Success at getting fair redundancy payments for Avlon staff

Back in March 2019, Darren Jones, the MP for Bristol North West, first wrote to the Government sharing his concerns about Avara’s Avlon site, and their 270 staff. The Avlon site is situated just outside Darren’s constituency. A number of constituents and their family members were employed at the site.

Avara Avlon Pharmaceutical Services Ltd, the company who now own the site, had become insolvent. Since that time it become clear, despite assurances when the company was sold 3 years ago by AstraZeneca, that staff would get above-statutory redundancy payments, which they had been contractually entitled to with AstraZeneca, only statutory redundancy payments were offered by Avara.

Darren has since written to the relevant government department (BEIS) and AstraZeneca, met with Unite union reps and former employees and raised this matter in Parliament on 11th July. Darren also applied for an Adjournment Debate with the Minister of 4 occasions (each attempt was unsuccessful) and worked with The Times to raise awareness of this gross unfairness. The Times have since ran several pieces on this matter this week.

Following these efforts, and those of former employees and Unite, Darren received for following statement from former owner, AstraZeneca:

Statement from AstraZeneca (17th July 2019):

We have decided to set aside funding of up to £12m, to be administered independently, to make sure our former employees at the Avlon site receive full severance should the ongoing administration of the site not generate enough funds to cover redundancy costs.

AstraZeneca remained closely involved in helping secure a future for the Avlon site following the sale to Avara, which was made in good faith in 2016. We have been engaged with the receivers since the company fell into administration. Last week, the deadline for bids for the site was reached and, since then, it has become apparent that there may not be sufficient funds to meet the redundancy costs of our former employees. 

Our success relies on the commitment and talent of our employees and our many partners in the UK and around the world who share our passion for science and for making a difference to the lives of patients.

Darren said:

“I’m delighted that after months of hard work from workers and unions, and my interventions with Astra Zeneca and the government, that workers are being paid the redundancy packages they deserve.

Whilst it should not have taken this level of intervention before employees got what they had been promised, I thank Astra Zeneca for listening, responding and making the right call.”